SCHEMBL279769

SCHEMBL279769

O=C(/C(Cl)=N/O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 11/20 0.56
CES1 P23141 10/20 0.56
CYP2C19 P33261 2/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 2/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46
PARP1 P09874 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTGS2 P35354 1/20 0.45
ALDH1A1 P00352 2/20 0.44
DAO P14920 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
TRPA1 O75762 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734683 1.00 CES2 (0.56) CES2CES1CYP2C19GAATSHR
SCHEMBL204419 0.80 CPT1B (0.52) CES2CES1MAPTCYP3A4BLM
SCHEMBL204420 0.80 CPT1B (0.52) CES2CES1MAPTCYP3A4BLM
SCHEMBL13943817 0.80 CES2 (0.62) CES2CES1TSHRMAPTCYP3A4
SCHEMBL2755934 0.80 CES2 (0.54) CES2CES1CYP2C19TSHRMAPT
SCHEMBL11797263 0.78 CES2 (0.60) CES2CES1MAPTL3MBTL1MAPK1
SCHEMBL11806648 0.78 CES2 (0.60) CES2CES1GAAMAPTTDP1
SCHEMBL11797258 0.78 CES2 (0.60) CES2CES1MAPTL3MBTL1MAPK1
SCHEMBL11806639 0.78 CES2 (0.60) CES2CES1GAAMAPTTDP1
Benzil SCHEMBL35210470 0.78 CES2 (0.82) CES2CES1CYP2C19TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3186226-B1 OXIME SULFONATE DERIVATIVES BASF SE (DE) 2020-06-17 EP disclosed
US-20190171099-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT BASF SE (DE) 2019-06-06 US disclosed
US-10241399-B2 Polymerizable composition comprising an oxime sulfonate as thermal curing agent BASF SE (DE) 2019-03-26 US disclosed
US-20170260132-A1 OXIME SULFONATE DERIVATIVES BASF SE (DE) 2017-09-14 US disclosed
US-9310677-B2 Polymerizable composition comprising an oxime sulfonate as thermal curing agent BASF (DE) 2016-04-12 US disclosed
US-20160060214-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT BASF SE (DE) 2016-03-03 US disclosed
EP-1636192-B9 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2015-07-01 EP disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
EP-1636192-B1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2014-01-15 EP disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
US-3986974-A AROYL-N-HYDROXYFORMIMIDOYL HALIDES AS BLEACH ACTIVATORS AMERICAN CYANAMID COMPANY (US) 1976-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 CES2 3450/4885CES1 3549/4885CYP2C19 146/4885
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL CES2 4439/4885CES1 1854/4885CYP2C19 2752/4885
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 CES2 3384/4885CES1 3557/4885CYP2C19 161/4885
US-10241399-B2 Polymerizable composition comprising an oxime sulfonate as thermal curing agent SULT1E1, COX6B1, SULT1A1 CES2 354/4885CES1 304/4885CYP2C19 189/4885
US-20170260132-A1 OXIME SULFONATE DERIVATIVES CBR3, CBR1, C1R CES2 254/4885CES1 267/4885CYP2C19 154/4885
US-20190171099-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT SULT1E1, COX6B1, SULT1A1 CES2 354/4885CES1 304/4885CYP2C19 189/4885
US-20160060214-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT SULT1E1, COX6B1, SULT1A1 CES2 354/4885CES1 304/4885CYP2C19 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.